02528nam a2200469 i 4500001001300000003000600013005001700019007001400036008004100050040003000091042000800121043001200129074001600141086002900157110013300186245042300319246006300742264006000805300004500865336000800910337001600918338001900934490002300953500003600976500005501012504004101067533010601108776020601214776018901420810006001609050002201669650004101691650004701732650004401779650003201823650005001855650002301905650003801928650003501966650003202001651002502033on1151883907OCoLC20200512084940.0he bmb024bbca200424s2018    dcua    bb   f000 0 eng c  aPUCPRbengerdacGPOdMvI  apcc  an-us---  a1043-B (MF)0 aY 4.L 11/4:S.HRG.114-8051 aUnited States.bCongress.bSenate.bCommittee on Health, Education, Labor, and Pensions.bSubcommittee on Children and Families,10aEpiPen price increases  :bhow regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY).30aHow regulatory barriers inhibit pharmaceutical competition 1aWashington :bU.S. Government Publishing Office,c2018.  aiii, 43 pages :billustrations ;c24 cm.  btxt  bh2rdamedia  bhe2rdacarrier1 aS. hrg. ;v114-805  aShipping list no.: 2019-0162-M.  aGPO Cataloging Record Distribution Program (CRDP).  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2018]e1 microfiche : negative.08iPrint version:aUnited States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families.tEpiPen price increasesw(DLC) 2018439951w(OCoLC)107840959308iOnline version:aUnited States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families.tEpiPen price increasesw(OCoLC)10789516401 aUnited States.bCongress.bSenate.tS. hrg. ;v114-805. 4aKF26b.L2733 2016 0aPrescription pricingzUnited States. 0aDrugsxLaw and legislationzUnited States. 0aPharmaceutical industryzUnited States. 0aCompetitionzUnited States. 0aDrug delivery devicesxPriceszUnited States. 7aCompetition.2fast 7aDrugsxLaw and legislation.2fast 7aPharmaceutical industry.2fast 7aPrescription pricing.2fast 7aUnited States.2fast